Nasdaq
$138.67▼ 2.78%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $13.94BShares out 100M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
25- 10.15Regular26.10.16 02:39SCHEDULE 13G/AOwnership#●●●#●●●
NEUROCRINE BIOSCIENCES INC
JPMorgan Chase & Co. has filed a Schedule 13G/A regarding its beneficial ownership in Neurocrine Biosciences Inc. (NBIX). This filing serves as a routine update on the institutional investor's equity position in the company.…more
$138.67-2.78%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.7After-hours26.10.08 07:153Ownership
NEUROCRINE BIOSCIENCES INC
Neurocrine Biosciences has filed a Power of Attorney authorizing company officers to prepare and submit Forms 3, 4, and 5 to the SEC on behalf of director Eiry Roberts. This filing facilitates the director's compliance with reporting requirements under Section 16 of the Securities Exchange Act.…more
$138.67-2.78%vs prev closeView filingShare - 9.28After-hours26.09.29 05:208-KKey event
NEUROCRINE BIOSCIENCES INC
Neurocrine Biosciences announced the resignation of Chief Medical Officer Sanjay Keswani, effective September 25, 2026, and the appointment of Eiry W. Roberts as his successor, effective September 28, 2026. Dr. Roberts will receive an annual base salary of $825,000 and equity grants including stock options, RSUs, and performance-vesting RSUs.…more
$138.67-2.78%vs prev closeView filingShare
24 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 2d agoAfter-hours26.10.23 05:15#●●●#●●●
Neurocrine Biosciences Announces Expert Publication on Prader-Willi Syndrome Treatment…more
Neurocrine Biosciences announced the publication of expert perspectives identifying hyperphagia in Prader-Willi syndrome as a neurobiologically driven condition. While the study highlights the potential of VYKAT XR as a treatment advancement, it does not provide new financial or regulatory approval data.…more
$138.67-2.78%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 5d agoPre-market26.10.20 21:31
●●●●●●●● ●●●●● ●●●●●●
Neurocrine Biosciences has launched a Phase 2 clinical study of NBI-1117567 for adults with mild to moderate Alzheimer's disease. The compound is an orally administered muscarinic agonist being evaluated as an adjunctive treatment for cognitive impairment.…more
$138.67-2.78%vs prev closeShareBenzinga - 10.16Pre-market26.10.16 21:36
●●●●●●●● ●●●●● ●●●●●●
Neurocrine Biosciences will present new real-world data regarding the clinical impact of classic congenital adrenal hyperplasia at the 2026 Endocrine Nurses Society Annual Symposium. As this is a data presentation without immediate financial impact, the outlook remains neutral.…more
$138.67-2.78%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report